The Efficacy and Safety of DLBS3233, A Combined Bioactive Fraction of Cinnamomum burmanii and Lagerstroemia speciosa Plants on The Endocrine-Metabolic Profile of Women with Polycystic Ovary Syndrome: A Randomized Clinical Trial.

Andon Hestiantoro Wiryawan Permadi Raymond Rubianto Tjandrawinata Budi Wiweko Mulyanusa Amarullah RitongaAde Indra FerrinaKanadi Sumapraja Raden Muharam Tono Djuwantono

Published in: International journal of fertility & sterility (2024)

Treatment with DLBS3233 100-mg daily in PCOS women demonstrated comparable efficacy to metformin- XR 750-mg twice daily in improving insulin resistance. However, the non-inferiority of DLBS3233 to metformin- XR remains inconclusive. DLBS3233 was more tolerable than metformin-XR (registration number: NCT01733459).

Keyphrases

polycystic ovary syndrome
insulin resistance
physical activity
metabolic syndrome
pregnancy outcomes
type diabetes
high fat diet induced
breast cancer risk
pregnant women